To wipe out global poverty, transfer money to the people who work hardest to earn it
Law firms are suffering in many areas, but patent infringement cases are flourishing
Half of U.S. renters spend at least 30 percent of their income on rent, with more than 11 million of them paying at least half of it and cutting back on food consumption
After crushing a Samwer brothers' clone attempt, online retail startup Fab expanded aggressively—right into a wave of layoffs
Hedge fund manager John Paulson has reversed dramatic losses with strong results for 2013, far outstripping hedge rivals' meager gains in a strong market
Sriracha is no longer a mere condiment—food manufacturers gigantic and small have turned the spicy, sweet, garlicky, hot sauce into a marketing flavor
After breaking up with Disney, he wants to produce sequels to Beverly Hills Cop and Top Gun
Northwestern's Kellogg School of Management reclaims the top stop after a two-year absence
Immigrant entrepreneurs and companies with intellectual property are more likely to hire
Santa Clara, Calif.
Founders: Dr. Gerrit Klaerner, Dr. Scott Rocklage, Dr. Detlef Albrecht, and Dr. Jerry Buysse
VC Investment over the last four quarters: $33 million
In October 2007, Relypsa was spun out of Amgen (AMGN) by the founders of a previous biotech startup, Ilypsa, which the biotech company had acquired for $420 million earlier that year. The 47-employee company is developing treatments for hyperkalemia, a potentially deadly condition in patients with heart and kidney disease. By acting in the gastrointestinal tract only, Relypsa's drugs would reduce the risk of side effects that can occur with treatments that are absorbed into the bloodstream.
Key to startup success: "... Intense focus, speed, and efficient use of capital. We have been able to take our lead product program from the initial clinical testing stage in a Phase 1 trial [investigational new drug] to Phase 2 clinical development in nine months, something that most drug discovery and development startups typically achieve ... in three to four years."